Markets

Standard BioTools Terminates Its Previously Announced Agreement To Sell Its Mass Cytometry Business To Multiplex Bio; Co. Enters Into A Definitive Agreement To Sell Its Mass Cytometry Business To Element Biosystems For $5.5M In Cash Payable

Sep 30, 2026 · 04:45 PM ET· updated 45m ago

Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences,

Why It Matters

Standard BioTools canceled one deal to sell a business unit. Now it's selling that same unit to a different buyer for $5.5 million instead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LAB0.75

+0.04 (+5.29%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.